Different Standard Of Polyvalent Antivenoms And Improve Quality Of Treatment Patients

1563 Words7 Pages
In order to compete with the existing standard of polyvalent antivenoms and improve the quality of treatment patients are currently receiving, we assembled criteria that would guarantee the creation of the most efficacious and safe product to combat envenomation. These criteria are the following: 1) The product must target many venoms. 2) It must have limited side effects. 3) It must have low toxicity. 4) It must be scalable and cost-effective. 5) The product must stimulate the immune system. The platform technology we have created satisfies all of the criteria. Our design is a DNA Origami-Aptamer-CpG complex that has the ability to target may different types of venoms. Though the specifics of the technology will be explained more in…show more content…
To test the quality of Polymamba, we will conduct both preclinical and clinical trials. These trials will be conducted according to the World Health Organization guidelines for the production control and regulation of snake antivenom immunoglobulins. Due to the severity of the cases of envenomation in Sub-Saharan Africa and Southeast Asia, we anticipate accelerated approval of Polymamba after conducting successful trials. More on FDA For our product, the main objective of preclinical trials will be to establish safety and efficacy. We will only preclinically assess Polymamba against the relevant snake venoms in Sub-Saharan Africa and Southeast Asia. The first step in our preclinical trials will be to evaluate how efficaciously Polymamba is able to neutralize the toxic activity of the snake venom that it is intended to act against. To determine this, we will carry out venom-neutralizing potency tests in mouse models. This test will be performed for each venom that Polymamba will be targeting. The first task in this test Is to determine the median lethal dose of venom. To establish what this dose is, five to six mice will be injected with various doses of venom through an intravenous route. After twenty-four hours, the deaths are recorded. We then determine the dose that induces death in fifty percent of the mice, also referred to as the median lethal dose, by using a non-parametric test, such as the Spearman-Karber method. Determining the neutralizing

    More about Different Standard Of Polyvalent Antivenoms And Improve Quality Of Treatment Patients

      Open Document